Comparing the performance characteristics of CSF-TRUST and CSF-VDRL for syphilis: a cross-sectional study

Weiming Gu, Yang Yang, Lei Wu, Sheng Yang, Lai-King Ng

ABSTRACT

Objective: In this study, we aimed to determine the performance characteristics of toluidine red unheated serum test on cerebrospinal fluids (CSF-TRUST) as compared to venereal disease research laboratory test on cerebrospinal fluids (CSF-VDRL) for laboratory the diagnosis of neurosyphilis.

Design: A cross-sectional study.

Setting: Sexually transmitted infections (STIs) clinics.

Participants and methods: CSF and serum samples were collected from 824 individual STD clinic patients who have syphilis and are suspected to progress to neurosyphilis within a 9-month period. CSF-VDRL and CSF-TRUST were performed parallelly on the same day when collected. Treponema pallidum particle agglutination (TPPA) tests were also performed on the CSF and the serum samples, and biochemical analysis of the CSF samples was also performed.

Results: The overall agreement between CSF-TRUST and CSF-VDRL was 97.3%. The reactive ratios of the CSF samples were 22.1% by CSF-TRUST and 24.8% by CSF-VDRL, respectively. All CSF-TRUST-reactive cases were reactive in the CSF-VDRL. Twenty-two cases with CSF-TRUST-negative were tested CSF-VDRL-reactive with low titres (1:1 to 1:4). Over 97% of the double-reactive CSF samples (CSF-VDRL and CSF-TRUST) had an identical titre or a titre within a two-fold difference. The agreement of CSF-TPPA and CSF-VDRL was 71.9%. Similarly, the agreement of CSF-TPPA and CSF-TRUST was 69.2%.

Conclusions: Our results revealed that CSF-TRUST could be used as an option for CSF examination in settings lacking CSF-VDRL.

Neurosyphilis can occur at any time in the course of syphilis, its symptoms and signs are usually non-specific. Some neurosyphilis cases remain asymptomatic.\(^1\)\(^2\) According to the WHO\(^3\) and the Center for Disease Control and Prevention (CDC USA),\(^4\) the venereal disease research laboratory test on cerebrospinal fluids (CSF-VDRL) is the method of choice for laboratory diagnosis of neurosyphilis. However, owing to the stability issues of VDRL antigens, no manufacturers in China are approved by the China State Food and Drug Administration Agency (SFDA) to supply the reagent commercially, which significantly hinders the correct and prompt diagnosis of neurosyphilis in Chinese hospital settings.\(^5\)

TRUST is a modification of the VDRL procedure by labelling the antigen with toluidine red particles.\(^6\) TRUST is mostly used in serum tests for laboratory diagnosis of syphilis. The performance of TRUST for serum...
Laboratory diagnosis of neurosyphilis

examination is similar to that of the rapid plasma regain (RPR). The TRUST reagents from commercial sources have been approved by the SFDA for syphilis diagnosis. Therefore, we are interested in determining whether TRUST can be used for CSF examination in suspected neurosyphilis cases. The objective of this study was to determine the performance characteristics of toluidine red unheated serum test on cerebrospinal fluids (CSF-TRUST) when compared to CSF-VDRL in CSF samples collected from 824 syphilis patients.

MATERIALS AND METHODS
CSF and serum samples
The criteria for diagnosis of syphilis and syphilis staging were those described by the National Center for STD Control, China CDC. The criteria for examining CSF of a syphilis patient in this study included one of the following: (1) having neurological or psychiatric signs or symptoms or (2) exhibiting serofast state for more than 2 years or (3) request from patients because of anxiety of neurosyphilis. The diagnosis of neurosyphilis in our hospital followed the criteria set by the China CDC. Briefly, a patient is diagnosed having neurosyphilis when meeting the following three criteria: (1) syphilis history with signs and/or symptoms of neurological damages and serum-reactive of non-treponemal-specific serological tests and reactive in treponemal-specific serological tests; (2) syphilis history with abnormal CSF examination results (white blood cell counts (WBC) >10^6/l and protein >500 mg/l) which cannot be explained otherwise and (3) syphilis history with CSF-VDRL-reactive.

CSF samples were collected using lumbar punctures from syphilis patients at the Shanghai Skin Disease Hospital (SSDH) in Shanghai during the period of June 2009–February 2011. CSF samples containing visible particles, exhibiting pink colours or having visible traces of blood were excluded from the study. Totally, 824 CSF samples from syphilis patients (each sample from one individual patient) were examined in this study. CSF samples were tested on the same day they were collected. CSF white blood cell counts were done within 2 h after the lumbar puncture, and other tests were conducted within 4 h.

Serum samples were also collected from individuals at the same time and tested for syphilis serology on same day.

The study was approved by the Shanghai Skin Disease Hospital Ethical Review Board. All participants provided informed consent in writing.

CSF-VDRL, CSF-TRUST and CSF-TPPA
The following practice was conducted to minimise potential bias from technicians. (1) Two technicians involved in the testing were blind from patients’ IDs; (2) CSF-VDRL and CSF-TRUST tests were performed by a separate technician, respectively and (3) The laboratory supervisor who was blind from patients’ IDs as well combined the two sets of testing results at the end of each day.

CSF samples were centrifuged prior to CSF-VDRL, CSF-TRUST and CSF-TPPA (Treponema pallidum particle agglutination) examinations which were performed parallelly. Semiquantitative tests of CSF-VDRL and CSF-TRUST were performed by a serially two-fold dilution of the CSF samples with 0.85% saline and tested by both methods. The highest dilution of a sample which gave a reactive result was then used to assign a titre value.

VDRL antigen with buffered saline was purchased from Becton, Dickinson and Company (Diagnostic Systems, Sparks, Maryland, USA). CF-VDRL tests were performed according to the manufacturer’s instruction with modifications as described by Larsen et al. A fresh antigen suspension was prepared within 2 h prior to VDRL reactions. A quantity of 10 µl of the prepared antigen was incubated with 50 µl CSF samples for 8 min with rotation at 180 rpm on a mechanical rotator.

CSF-TRUST tests were performed using the TRUST reagent from the Shanghai Rongsheng Biotech Co (Shanghai, China) according to the routine for serum testing, according to the manufacturer’s instructions. The TRUST antigen suspension was mixed with CSF or diluted CSF samples on a white card; the formation of red clumps indicated a reactive result.

CSF-TPPA tests were conducted using the Serodia-TPPA reagent from Fujirebio Diagnostics Inc (Malven, Pennsylvania, USA). CSF sample and sensitised gelatin particles were added to a microtitre well and incubated at room temperature for 2 h. Results were observed according to the manufacturer’s instructions.

WBC counts and biochemical analysis of CSF
CSF samples were subjected to WBC counts and biochemical tests (Hitachi 7020 and Backman-IMMAGE800) to determine levels of chloride, sugar, total protein and albumin. The normal ranges of these markers and predicted values in neurosyphilis were those previously described. Test results for samples with inconsistent CSF-VDRL and CSF-TRUST testing results were analysed.

Serum-TRUST and serum-TPPA
Serum-TRUST and serum-TPPA tests were conducted according to the manufacturer’s instructions using the Shanghai Rongsheng Biotech Co TRUST reagent and the Serodia-TPPA reagent from Fujirebio Diagnostics Inc (Malven, Pennsylvania, USA), respectively.

Statistical analysis
The program SPSS V13.0 from IBM (IBM Corp, New York, USA) was used according to the publisher’s instruction. McNemar’s test was used to compare paired proportions. A p value of <0.05 was considered significant.

RESULTS
Agreement of results between CSF-VDRL, CSF-TRUST and CSF-TPPA tests
The 824 CSF samples were collected from 824 syphilis patients comprising 456 male and 368 female syphilis patients.
patients. The average age of the patients was 42.3 years, ranging from 10 to 82 years.

For undiluted CSF samples, an overall agreement of 97.3% was observed (95% CI 96.2% to 98.4%) between CSF-VDRL and CSF-TRUST (table 1). Among the 824 CSF samples, reactive proportions for VDRL and TRUST were 24.8% and 22.1%, respectively. The reactive percents were significantly different between CSF-VDRL and CSF-TRUST (p < 0.001).

In addition, the agreement of CSF-TPPA and CSF-VDRL was 71.9%. The reactive proportion was significantly higher for CSF-TPPA (52.9%) than that for CSF-VDRL (24.8%) (p < 0.001, table 2). Similarly, the agreement of CSF-TPPA and CSF-TRUST was 69.2%, and the reactive percents for CSF-TPPA and CSF-TRUST were 52.9% and 22.1%, respectively (p < 0.001, table 2).

**Comparison of titres of CSF-VDRL and CSF-TRUST**

All 620 CSF samples with negative CSF-TRUST test results were also tested negative by the CSF-VDRL method. There were 22 CSF samples which were CSF-VDRL-reactive but CSF-TRUST-negative (figure 1). There were 94 CSF samples with identical titres, accounting for 51.6% of the CSF samples with both VDRL-reactive and TRUST-reactive (94/182, shadowed cells of figure 1). Moreover, there were 83 CSF samples with only two-fold differences in the titres of VDRL and TRUST, accounting for 45.6% of the CSF samples with both VDRL-reactive and TRUST-reactive (83/182, open boxes of figure 1). Therefore, the per cent of CSF double-reactive samples (n=182) which had identical or a two-fold difference titres was 97.2%.

Five CSF samples with double-reactive (5/182, 2.8%) displayed significantly higher VDRL titres than TRUST (four-fold difference), whereas no CSF samples had a significantly higher TRUST titres than that of CSF-VDRL.

**Analysis of samples with inconsistent results of CSF-VDRL and CSF-TRUST**

All the CSF-TRUST-reactive samples in this study were also CSF-VDRL-reactive (n=182). On the other hand, there were 22 CSF-VDRL-reactive samples (2.7%) which tested negative by the CSF-TRUST method. These 22 CSF samples were CSF-TPPA-reactive. The serum antibody titres of these patients were in the range 1 : 4 to 1 : 64 for serum-TRUST and had a titre of higher than 1 : 640 for serum-TPPA.

The 22 patients comprised neurosyphilis (n=16), primary syphilis (n=1), secondary syphilis (n=3) and latent syphilis (n=2) (table 3). Three cases had a CSF-VDRL titre of 1 : 2 or 1 : 4, whereas the rest 19 cases exhibited CSF-VDRL-reactive in undiluted CSF.

WBC and biochemical analysis were performed on the 22 CSF samples with inconsistent CSF-VDRL and CSF-TRUST results (table 3). Seven of the 22 CSF samples showed a remarkable increase in WBC counts (>8×10⁶/l), which comprised four neurosyphilis cases, one latent syphilis and two secondary syphilis patients. Eight CSF samples had slightly lower chloride concentration than the normal ranges, comprising seven samples from neurosyphilis and one from latent syphilis cases. Two samples exhibited abnormal CSF sugar concentrations, which were from neurosyphilis patients. Four CSF samples from one latent, one primary and two neurosyphilis cases had slightly higher levels of total proteins than the normal ranges. Twelve CSF samples exhibited increased albumin

### Table 1: Agreement of results between CSF-VDRL and CSF-TRUST

<table>
<thead>
<tr>
<th>Method</th>
<th>CSF-VDRL (n, %)</th>
<th>CSF-TRUST (n, %)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>CSF-TRUST (n, %)</td>
<td>+</td>
<td>182 (22.1)</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>22 (2.7)</td>
</tr>
<tr>
<td>Total</td>
<td>204 (24.8)</td>
<td>620 (75.2)</td>
</tr>
</tbody>
</table>

CSF-TRUST, toluidine red unheated serum test on cerebrospinal fluids; CSF-VDRL, venereal disease research laboratory test on cerebrospinal fluids.

### Table 2: Agreement of results between CSF-VDRL and CSF-TPPA or between CSF-TRUST and CSF-TPPA

<table>
<thead>
<tr>
<th>Method</th>
<th>CSF-VDRL (n, %)</th>
<th>Subtotal</th>
<th>CSF-TRUST (n, %)</th>
<th>Subtotal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>CSF-TPPA (n, %)</td>
<td>+</td>
<td>204 (24.8)</td>
<td>232 (28.2)</td>
<td>436 (52.9)</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>0 (0.0)</td>
<td>388 (47.1)</td>
<td>388 (47.1)</td>
</tr>
<tr>
<td>Subtotal</td>
<td>204 (24.8)</td>
<td>620 (75.2)</td>
<td>824</td>
<td>824</td>
</tr>
<tr>
<td>p Value</td>
<td>&lt;0.001*</td>
<td></td>
<td>&lt;0.001†</td>
<td></td>
</tr>
</tbody>
</table>

*Comparison of reactive per cents for CSF-VDRL and CSF-TPPA.
†Comparison of reactive per cents for CSF-TRUST and CSF-TPPA.

CSF-TRUST, toluidine red unheated serum test on cerebrospinal fluids; CSF-VDRL, venereal disease research laboratory test on cerebrospinal fluids; CSF-TPPA, treponema palladium particle agglutination test on cerebrospinal fluids.
concentrations, comprising one latent syphilis, three secondary syphilis and eight neurosyphilis cases.

**DISCUSSION**

A combination of biochemical, WBC examination and VDRL analysis of CSF sample is the recommended method for the laboratory diagnosis of neurosyphilis. For patients who are neurologically asymptomatic, assessment of the efficacy of neurosyphilis treatment relies on negative CSF-TRUST titres (n=5). An identical titre of CSF-VDRL and CSF-TRUST indicates samples having two-fold dilution difference between CSF-VDRL-reactive, but CSF-TRUST non-reactive (n=22). Horizontal strike boxes indicate that CSF-VDRL titres are significantly higher than CSF-TRUST titres (n=5). Negative; CSF-TRUST, toluidine red unheated serum test on cerebrospinal fluids; CSF-VDRL, venereal disease research laboratory test on cerebrospinal fluids.

Discrepancy between CSF-VDRL and CSF-TRUST was observed in this study. First, 2.8% of double-reactive samples (5/182) showed significantly higher VDRL titres than TRUST (four-fold difference). Second, the 22 CSF-TRUST non-reactive samples had low titres of CSF-VDRL, and a portion of these samples also had abnormal CSF biochemical parameters such as WBC counts, concentrations of sugar, chloride, total protein and albumin. Third, six cases were diagnosed as method is reagent and operator dependent. In their study, the agreement of CSF-VDRL results between two top CDC laboratories was 87%. The situation is even more challenging in China as there are no commercial VDRL reagents approved by the SFDA for CSF-VDRL examination. On the other hand, the TRUST method is a modified version of the VDRL test, the toluidine red particle-labelled antigen is stable at room temperature (Gu et al, unpublished data), can be performed as a simple agglutination test; and there are multiple commercial TRUST reagents approved by SFDA for use in serum examination in the laboratory diagnosis of syphilis.

We investigated the potential use of the TRUST method for the laboratory diagnosis of neurosyphilis with CSF samples collected from 824 syphilis patients. The agreement of CSF-VDRL and CSF-TRUST was 97.3%, and 97.2% of the reactive CSF samples had similar titres (within two-fold dilutions) determined by the two methods. Moreover, the agreements between CSF-TRUST and CSF-VDRL (71.9%) and between CSF-TPPA and CSF-TRUST (69.2%) were similar. This study suggests that CSF-TRUST could be an option in CSF-VDRL unavailable settings.

Petit et al evaluated the performance of the TRUST method against the VDRL method on serum samples for the diagnosis of syphilis. Their results indicated a 99.7% agreement between the two methods. Recent publication by Jiang et al revealed the potential use of CSF-TRUST in neurosyphilis diagnosis by examining archived CSF samples from neurosyphilis.

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Biochemical analysis of 22 CSF samples with VDRL-reactive, but TRUST-non-reactive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical diagnosis*</td>
<td>Number of cases</td>
</tr>
<tr>
<td>Neurosyphilis</td>
<td>16</td>
</tr>
<tr>
<td>Primary</td>
<td>1</td>
</tr>
<tr>
<td>Secondary</td>
<td>3</td>
</tr>
<tr>
<td>Latent</td>
<td>2</td>
</tr>
<tr>
<td>Total/range</td>
<td>22</td>
</tr>
</tbody>
</table>

*Diagnosis was made by physician’s presumptive diagnosis, pending laboratory tests.
†Number of samples with abnormal values.
CSF WBC: normal range 0–10⁶/l.
CSF chloride: normal range 122–132 mmol/l.
CSF sugar: normal range 2.5–4.5 mmol/l.
CSF total protein: normal range 0.15–0.45 mg/l.
CSF-albumin: normal range 0.139–0.246 mg/l.
CSF-TRUST, toluidine red unheated serum test on cerebrospinal fluids; CSF-VDRL, venereal disease research laboratory test on cerebrospinal fluids; WBC, white blood cell count.
‘non-neurosyphilis’ exhibited CSF-VDRL-reactive but CSF-TRUST non-reactive, and these cases also showed abnormal values of CSF biochemical markers. This suggests that CSF-TRUST is less sensitive than CSF-VDRL when the antibody titres are low. Therefore, while CSF-TRUST-reactive could be diagnostic of neurosyphilis, CSF-TRUST non-reactive patients should be further investigated to rule out neurosyphilis.

Other earlier studies have indicated that negative CSF treponemal-specific tests may not exclude the diagnosis of neurosyphilis.\(^1\)\(^\text{21}\) We also examined the agreement of a CSF treponemal-specific test CSF-TPPA to CSF-VDRL and CSF-TRUST. The low per cent of agreement (\(~70\%\) suggest) that CSF-TPPA is not a good method for laboratory diagnosis of neurosyphilis. However, we did not examine the sensitivity and specificity of CSF-TPPA for neurosyphilis in our study.

The use of CSF-RPR in neurosyphilis diagnosis have also been evaluated by others.\(^1\)\(^\text{19}\)\(^\text{22}\)\(^\text{23}\)\(^\text{24}\)\(^\text{25}\) Marra et al.\(^\text{22}\)\(^\text{23}\) have recently evaluated CSF-RPR performance on 149 syphilis patients and found that the sensitivities of CSF-RPR for laboratory-diagnosed neurosyphilis was 56.4% (serum RPR method) or 59% (CSF RPR method) compared to 71.8% of CSF-VDRL.\(^\text{22}\) CSF-RPR also showed lower titres than CSF-VDRL.\(^\text{22}\) Study by Castro et al.\(^\text{23}\) revealed similar sensitivities for CSF-RPR (75%) and CSF-VDRL (70.8%), and that both methods had specificities of over 99%. The discrepancy of the results from these two studies may, at least partly, be owing to the choice of negative and positive controls.\(^\text{21}\)

The use of CSF-TRUST for the evaluation of treatment effects of neurosyphilis remains unclear. It was reported that the normalisation time (median months) of CSF-VDRL and serum RPR was 3.9 and 4.4 months after treatments, respectively.\(^\text{18}\) Syphilis stages and HIV-coinfections are some of the factors influencing the normalisation time.

Our study has the limitations of defining neurosyphilis status in the study subjects because of the lack of clinical data. It is difficult to interpret the performance of CSF-TRUST in terms of its specificity, sensitivity and predictive values in sexually transmitted infections (STIs) clinic settings. It seems that CSF-TRUST and CSF-VDRL are congruence in most cases, but CSF-TRUST is less sensitive than CSF-VDRL. Nevertheless, our results suggested that CSF-TRUST may be used as an alternative for laboratory diagnosis of neurosyphilis in clinical settings with CSF-VDRL unavailable.

**Acknowledgements**  We especially thank Raymond SW Tsang (National Microbiology Laboratory, Public Health Agency of Canada) and Mingmin Liao (Vaccine and Infectious Disease Organization, University of Saskatchewan, Canada) for their critiques and editing of this manuscript. We thank Yue Chen (Epidemiology and Community Medicine, University of Ottawa) for reviewing the statistical analysis.

**Contributors**  WG was the principal investigator and lead writer. YY was the co-investigator. LW and SY were technical personnel at SSDH. LKN is a collaborator from NML Canada. YY, LW and SY significantly contributed to acquisition of data. All authors helped plan the study, interpret data and critically revise successive drafts of the manuscript.

**Funding**  This work was supported by the Shanghai Nature Science Fund, Shanghai, China (602214084 and #09DZ1907104).

**Competing interests**  None.

**Patient consent**  Obtained.

**Ethics approval**  Ethics board of the Shanghai Skin Disease Hospital, Shanghai, China.

**Provenance and peer review**  Not commissioned; externally peer reviewed.

**Data sharing statement**  There are no additional data available.

**REFERENCES**